Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks likely to meet or exceed Wall Street’s lofty expectations.

Leidos (LDOS)

Consensus Price Target: $209.07 (31.3% implied return)

Formed through the split of IT services company SAIC, Leidos (NYSE: LDOS) offers technology and engineering solutions such as military training systems for the defense, civil, and health markets.

Why Are We Positive On LDOS?

1. Sales pipeline is in good shape as its backlog averaged 20.2% growth over the past two years
2. Operating margin improvement of 3.9 percentage points over the last five years demonstrates its ability to scale efficiently
3. Share buybacks catapulted its annual earnings per share growth to 28.2%, which outperformed its revenue gains over the last two years

At $159.24 per share, Leidos trades at 13.1x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.

Boston Scientific (BSX)

Consensus Price Target: $100.81 (58.8% implied return)

Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.

Why Could BSX Be a Winner?

1. Core business can prosper without any help from acquisitions as its organic revenue growth averaged 16.6% over the past two years
2. Performance over the past five years shows its incremental sales were extremely profitable, as its annual earnings per share growth of 26% outpaced its revenue gains
3. Free cash flow margin increased by 7 percentage points over the last five years, giving the company more capital to invest or return to shareholders

Boston Scientific’s stock price of $63.50 implies a valuation ratio of 18.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

Genpact (G)

Consensus Price Target: $48.64 (28.9% implied return)

Originally spun off from General Electric in 2005 to provide business process services, Genpact (NYSE: G) is a global professional services firm that helps businesses transform their operations through digital technology, AI, and data analytics solutions.

Why Are We Fans of G?

1. Share repurchases have increased shareholder returns as its annual earnings per share growth of 11.5% exceeded its revenue gains over the last five years
2. Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
3. ROIC punches in at 18.2%, illustrating management’s expertise in identifying profitable investments, and its rising returns show it’s making even more lucrative bets

Genpact is trading at $37.74 per share, or 9.4x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.